LUCENTIS 10mg/ml Price

Overview

Welcome to Dwaey, specifically on LUCENTIS 10mg/ml page.
This medicine contains an important and useful components, as it consists of
Ranibizumabis available in the market in concentration

Name

Ranibizumab

Precaution

Patient w/ risk factors for retinal pigment epithelial tears, history of stroke or transient ischaemic attack, uncontrolled HTN, previous intravitreal inj, active systemic infections, proliferative diabetic retinopathy, diabetic macular oedema due to type 1 DM. Discontinue treatment if rhegmatogenous retinal detachment or stage 3 or 4 macular hole develops. Diabetic patients w/ glycosylated Hb over 12%. Lactation: Unknown if distributed in milk; use caution

Indication

Wet ARMD, Central retinal vein occlusion, Diabetic macular edema

Contra indication

Active or suspected ocular or periocular infection, active severe intraocular inflammation, signs of irreversible ischaemic visual function loss in patients w/ retinal vein occlusion.

Side Effect

>10% Conjunctival hemorrhage (43-77%),Eye pain (17-37%),Vitreous floaters (3-32%),Incr IOP (8-24%),Vitreous detachment (7-22%),Eye irritation (4-19%),Intraocular inflammation (5-18%),Headache (2-15%),Upper resp tract infection (2-15%),Retinal disorder (13%),Blepharitis (3-13%),Retinal degeneration (1-11%) 1-10% Conjunctival hyperemia (9%),Posterior capsule opacification (8%),Injection site hemorrhage (5%),Vitreous hemorrhage (4%)

Pregnancy Category ID

3

Mode of Action

Humanized monoclonal antibody to VEGF-A, inhibits VEGF-A-induced ocular neovascularization.

Interaction

May enhance the adverse/toxic effect of belimumab. Serious intraocular inflammation may occur when used adjunctively w/ verteporfin photodynamic therapy (PDT).

Pregnancy Category Note

Information not available

Adult Dose

Child Dose

Renal Dose

Administration